H.C. Wainwright lowered the firm’s price target on Pliant Therapeutics to $36 from $48 and keeps a Buy rating on the shares following the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Pliant Therapeutics, Inc. (PLRX) Q1 Earnings Cheat Sheet
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Pliant Therapeutics announces accelerated bexotegrast development plan
Questions or Comments about the article? Write to editor@tipranks.com